Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.

NCT04016935 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.

NCT NCT04016935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04016935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
Lead sponsor
Myriad Genetic Laboratories, Inc.
Phase
Observational
Overall status
Terminated
Start date
July 2, 2019
Completion date
March 31, 2022
Enrollment
855 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

primary invasive breast cancer